The Lancet in conversation with

Niall Boyce welcomes Professor Stuart Pocock, author of two Lancet papers, published 35 years apart: 1991's "Can meta-analyses be trusted?" and 2026's "What makes a meta-analysis believable?" They discuss what makes a trustworthy meta, and how the smart clinician should use the totality of evidence to inform clinical care. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01087-1/fulltext

What cardiovascular issues can women experience in pregnancy, and why? Lancet editors Niall Boyce and Chloe Wilson talk with Professor Garima Sharma, one of the authors of a new Series of papers aiming to bring the cardiovascular health of pregnant women into the mainstream of primary and secondary care. Click here to read the full series: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01235-3/fulltext https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00190-1/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01234-1/fulltext

What are mRNA vaccine, how do they work, and how might they be used for in the future? And why is there a gap between the evidence and some people’s perception of their safety and efficacy? Niall Boyce from The Lancet talks to Anna Blakney, biomedical engineer and one of the authors of new Review paper "Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective". Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00512-X/abstract

What are cardiometabolic long-term conditions? To mark the publication of a new Lancet Series, editors Niall Boyce and Flávia Geraldes talk to Professor Kamlesh Khunti of the University of Leicester. They learn about a new way of conceptualising common medical conditions that has the potential to radically transform both health services and patient outcomes. Click here to read the full series: https://www.thelancet.com/series-do/lancet-series-cardiometabolic-multiple-long-term-conditions

In this episode of The Lancet In Conversation With, editors Niall Boyce and Bea Gómez Pérez-Nievas are joined by three leading researchers to discuss highlights from The Lancet's special issue on neurology. The conversation covers three landmark studies: the PADOVA trial of prasinezumab in early-stage Parkinson's disease, the ORATORIO-HAND study extending ocrelizumab treatment to wheelchair-using patients with progressivemultiple sclerosis, and the HEAD study comparing tau PET tracers in Alzheimer's disease — each representing a significant step forward in the field. The guests also reflect on the broader forces reshaping neurology: the push toward earlier, biomarker-guided intervention, cross-specialty learning between the multiple sclerosis, Alzheimer's, and Parkinson's fields, and emerging platforms such as CAR T-cell therapies and blood-based biomarkers. From the transformative success of spinal muscular atrophy treatment to the prospect of an EBV vaccine preventing MS, the discussion strikes a note of cautious optimism about a specialty that is entering a new therapeutic era. Visit the lancet.com to discover more